Measures of effect: relative risks, odds ratios, risk difference, and 'number needed to treat'.
暂无分享,去创建一个
C Zoccali | F. Dekker | C. Wanner | C. Zoccali | K. Jager | G. Tripepi | Carmine Zoccali | F W Dekker | C Wanner | K J Jager | G Tripepi
[1] R. M. Pilkey,et al. Thrombophilia and the risk for hemodialysis vascular access thrombosis. , 2005, Journal of the American Society of Nephrology : JASN.
[2] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[3] S. Yusuf,et al. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. , 2000 .
[4] M. Szklo,et al. Epidemiology: Beyond the Basics , 1999 .
[5] B. Fivush,et al. Incidence of atherosclerosis by race in the dialysis morbidity and mortality study: a sample of the US ESRD population. , 2005, Journal of the American Society of Nephrology : JASN.